Increased levels of hemoglobin, transferrin saturation, and serum ferritin were observed in patients with an eGFR ~64 mL/min per 1.73 m2 and chronic heart failure who received intravenous ferric carboxymaltose in the Ferinject Assessment in Patients with Iron Deficiency and Chronic Heart Failure (FAIR-HF) trial [7]. The gene discussed is TF; the disease is Iron deficiency anemia.